Vyndamax (tafamidis) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:
	e.g., chart notes or la	ns completely and legibly. Attach any additional documentation that is b data, to support the authorization request). Information contained in HIPAA.
MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		I
CITY:		STATE: ZIP CODE:
PATIENT INSURANCE ID N	IUMBER:	I
PATIENT'S AUTHORIZED RI AUTHORIZED REPRESENTA	EPRESENTATIVE (IF A	APPLICABLE): BER:
PRESCRIBER INFORMATION	ON	
LAST NAME:		FIRST NAME:
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:
NPI NUMBER:		DEA NUMBER:
PHONE NUMBER:		FAX NUMBER:
STREET ADDRESS:		
CITY:		STATE: ZIP CODE:
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:
MEDICATION OR MEDICA	AL DISPENSING INFO	RMATION_
MEDICATION NAME:		
OOSE/STRENGTH: FREQUENCY:		LENGTH OF QUANTITY: THERAPY/REFILLS:
NEW THERAPY	RENE	NAL IF RENEWAL: DATE THERAPY INITIATED:
DURATION OF THERAPY (S	SPECIFIC DATES):	



Vyndamax (tafamidis) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
Continued on next page		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
,	,	·
2. LIST DIAGNOSES:		ICD-10:
☐ Transthyretin amyloid cardiomyopathy(
☐ Other diagnosis:ICD-1	LU Code(s):	
3. REQUIRED CLINICAL INFORMATION	: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Clinical Information:		
Does patient have a history of heart f	ailure with at least one prior hospitaliza	ation for heart failure? Yes No
1 · · · · · · · · · · · · · · · · · · ·	heart failure without hospitalization(d	
volume overload or elevated intracar	diac pressures requiring treatment with	n a diuretic)? 🗆 Yes 🗆 No
		v
-	t with or suggestive of amyloidosis? \Box	Yes □ No Please submit
echocardiogram report.		
Does patient have an N-terminal pro-	B-type natriuretic peptide(NT-proBNP)	level greater than or equal to
600pg/mL? □ Yes □ No Please subm		iever greater than or equal to
Does patient have a B-type natriuretic	c peptide(BNP) level greater than or eq	ual to 100pg/ml? ☐ Yes ☐ No Please
submit lab report.		
Does patient have a New York Heart	Association(NYHA) class I, II or III diseas	e? 🗆 Yes 🗆 No
1 · · · · · · · · · · · · · · · · · · ·	hyretin precursor protein present via a	Grade 2 or Grade 3 positive Tc-
pyrophosphate(PYP) scan? Yes I	No Please submit imaging report.	
Are nationt's serum immunofivation	esults within normal range? Yes	In Please submit lab report
<u> </u>	esults above the upper range of norma	
Please submit lab report.	counts above the appearange or norma	in instead on the lab report. In res in the
Are patient's urine immunofixation re	esults within normal range? Yes No	o Please submit lab report.
Are patient's urine immunofixation re	esults above the upper range of normal	listed on the lab report? ☐ Yes ☐ No
Please submit lab report.	-	
•	ree light-chain assay results within nor	mal range? Yes No
Please submit lab report.		



Vyndamax (tafamidis) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

VIEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Are patient's serum electrophoresis/free light-chain assay results above the upper range of normal listed on the lab report? Yes No Please submit lab report.
Is patient's free light-chain level within normal range? Yes No Please submit lab report. Is patient's free light-chain level above the upper range of normal on the lab report? Yes No Please submit lab report.
Does patient have a confirmed transthyretin precursor protein present via a Grade 1 positive Tc-pyrophosphate(PYP) scan? No Please submit imaging report.
Is patient's ATTR amyloid histologically confirmed and typed from an endomyocardial tissue biopsy specimen? □ Yes □ No Please submit tissue biopsy.
Is patient's ATTR amyloid histologically confirmed and typed from ANY tissue biopsy specimen? ☐ Yes ☐ No Please submit tissue biopsy.
Does a hematology consultation report rule out light-chain disease? ☐ Yes ☐ No Please submit report.
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that
the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical
information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification: Date:
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If
you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents
of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX)

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

Prime THERAPEUTICS*

and arrange for the return or destruction of these documents.